ГоловнаArchive of numbers2021Volume 29, issue 2 (107)The use of antipsychotics in targeted therapy of schizophrenia — prospects and challenges (for example, amisulpride).
Title of the article The use of antipsychotics in targeted therapy of schizophrenia — prospects and challenges (for example, amisulpride).
Authors Khaustova Olena
Assonov Dmytro
In the section HELP TO PRACTICAL PHYSICIAN
Year 2021 Issue Volume 29, issue 2 (107) Pages 83-89
Type of article Scientific article Index UDK 616.895.8-085:615.21/26-037 Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V29-is2-2021-14 Personalized medicine is an innovative approach that takes into account the biological, social and psychological characteristics of people in the development of preventive drugs and treatment of diseases. The goals of personalized medicine in psychiatry are to anticipate a person’s susceptibility to disease, achieve accurate diagnosis, and facilitate a favorable response to treatment. This article analyzes the information presented in the literature on use of antipsychotics in treatment of schizophrenia from the standpoint of personalized medicine with the aim to draw up recommendations for improving the effectiveness of psychotic symptoms therapy and set the vector for further scientific research in this direction. Despite the existence of many international and local guidelines and protocols for antipsychotic therapy, there is still the problem of early determination of which antipsychotic will be effective and safe for a particular patient — before the most effective drug is determined, patients are usually treated with various antipsychotics. In the treatment of schizophrenia, no antipsychotic drug or dosage is universal. Therefore, to maximize the useful effect and minimize the risk of side effects, numerous individual characteristics of each individual user must be considered. In particular, such characteristics as sex, age, clinical features (dominant symptoms, time of onset of symptoms and their intensity), comorbid mental and somatic disorders, presence/absence of bad habits, response to previous therapy (in case of such) should be taken into account. Given the possibility of flexible dosage of amisulpride and its significant effectiveness in reducing various groups of symptoms in various categories of patients, it has the potential for widespread use in personalized psychiatry.
Key words personalized medicine, atypical antipsychotics, effectiveness of therapy
Access to full text version of the article pdf download
Bibliography 1. Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises // BMC medicine. 2013 Dec;11(1):132. https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-132. 2. Haustova, O., & Omelânovič, V. (2020). Sučasnì pìdhodi do dìagnostiki ta nadannâ dopomogi pacìêntam na prodromalʹnomu etapì šizofrenìï // Psychosomatic Medicine and General Practice, 5(1), e0501232-e0501232. 3. Schoenbaum M, Sutherland JM, Chappel A, Azrin S, Goldstein AB, Rupp A, Heinssen RK. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States // Schizophrenia bulletin. 2017 Apr 7;43(6):1262-72. doi: 10.1093/schbul/sbx009. 4. Juckel, G., & Morosini, P. L. (2008). The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia // Current opinion in psychiatry. 2008. 21(6), 630–639. https://doi.org/10.1097/YCO.0b013e328314e144. 5. FDA, U. (2013). Paving the way for personalized medicine. FDA's Role in a new Era of Medical Product Development. US Department of Health and Human Services, 1-61. URL: https://www.fdanews.com/ext/resources/files/10/10-28-13-Personalized-Medicine.pdf. 6. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618. DOI: 10.17226/13284. 7. Haustova, O. O., Assonov D. O. . Kombìnovana terapìâ antipsihotikami: pro et contra // НейроNews. 2021. 1 (122), 28-33. 8. Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry. 2006 Mar;39(02):41-6. doi: 10.1055/s-2006-931540. PMID: 16555163. 9. Li, L., Li, L., Shang, D. W., Wen, Y. G., & Ning, Y. P. (2020). A systematic review and combined meta‐analysis of concentration of oral amisulpride // British Journal of Clinical Pharmacology, 86(4), 668-678. 10. Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., … Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. DOI: 10.1016/s0140-6736(19)31135-3. 11. Buckley, P. F., & Miller, B. J. (2017). Personalized medicine for schizophrenia. npj Schizophrenia, 3(1), 2. DOI: https://doi.org/10.1038/s41537-016-0001-5. 12. Howard, R., Cort, E., Bradley, R., Harper, E., Kelly, L., Bentham, P., … Gray, R. (2018). Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomized, controlled, double-blind trial. The Lancet Psychiatry, 5(7), 553–563. doi:10.1016/s2215-0366(18)30141-x. 13. Psarros, C., Theleritis, C. G., Paparrigopoulos, T. J., Politis, A. M., & Papadimitriou, G. N. (2009). Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. International journal of geriatric psychiatry, 24(5), 518–522. https://doi.org/10.1002/gps.2146. 14. Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The lancet. Psychiatry, 7(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X. 15. Preda, A., & Shapiro, B. B. (2020). A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert opinion on drug safety, 19(12), 1529–1538. https://doi.org/10.1080/14740338.2020.1832990. 16. Gallego, J. A., Nielsen, J., De Hert, M., Kane, J. M., & Correll, C. U. (2012). Safety and tolerability of antipsychotic polypharmacy. Expert opinion on drug safety, 11(4), 527–542. https://doi.org/10.1517/14740338.2012.683523. 17. Mas, S., Gassó, P., Rodríguez, N., Cabrera, B., Mezquida, G., … Lobo, A. (2019). Personalized medicine begins with the phenotype; identifying antipsychotic response phenotypes in a first episode psychosis cohort. Acta Psychiatrica Scandinavica. doi:10.1111/acps.13131. 18. Torrisi, S. A., Laudani, S., Contarini, G., De Luca, A., Geraci, F., Managò, F., … Leggio, G. M. (2020). Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals, 13(11), 365. doi:10.3390/ph13110365. 19. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular psychiatry, 17(12), 1206–1227. https://doi.org/10.1038/mp.2012.47. 20. Scheggia, D., Mastrogiacomo, R., Mereu, M., Sannino, S., Straub, R. E., Armando, M., Managò, F., Guadagna, S., Piras, F., Zhang, F., Kleinman, J. E., Hyde, T. M., Kaalund, S. S., Pontillo, M., Orso, G., Caltagirone, C., Borrelli, E., De Luca, M. A., Vicari, S., Weinberger, D. R., … Papaleo, F. (2018). Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nature communications, 9(1), 2265. https://doi.org/10.1038/s41467-018-04711-w. 21. Nakajima, S., Gerretsen, P., Takeuchi, H., Caravaggio, F., Chow, T., Le Foll, B., ... & Graff-Guerrero, A. (2013). The potential role of dopamine D3 receptor neurotransmission in cognition. European Neuropsychopharmacology, 23(8), 799-813. 22. Shin, S., Kim, S., Seo, S., Lee, J. S., Howes, O. D., Kim, E., & Kwon, J. S. (2018). The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11 C]-raclopride PET study with aripiprazole. Translational psychiatry. 2018 Apr 24;8(1):87. DOI: 10.1038/s41398-018-0134-6. PMID: 29686254; PMCID: PMC5913226. 23. Harrison, T. S., & Perry, C. M. (2004). Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. DOI: 10.2165/00003495-200464150-00010. PMID: 15257633. 24. Casey, A. B., & Canal, C. E. (2017). Classics in Chemical Neuroscience: Aripiprazole. ACS Chem Neurosci. 2017 Jun 21;8(6):1135-1146.. DOI: 10.1021/acschemneuro.7b00087. 25. Mailman, R. B., & Murthy, V. (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Current pharmaceutical design, 16(5), 488-501. DOI: 10.2174/138161210790361461. 26. Citrome, L., Eramo, A., Francois, C., Duffy, R., Legacy, S. N., Offord, S. J., Krasa, H. B., Johnston, S. S., Guiraud-Diawara, A., Kamat, S. A., & Rohman, P. (2015). Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric disease and treatment, 11, 3095–3104. DOI: https://doi.org/10.2147/NDT.S91917. 27. Pandarakalam, J. P. (2019). Combination Therapy for Treatment Resistant Schizophrenia. British Journal of Medical Practitioners, 12(2). BJMP 2019;12(2):a016. 28. Mossaheb N & Kaufmann R M. Role of Aripiprazole in treatment-resistant Schizophrenia. Neuropsychiatr Dis Treatment 2012; 8:235-44. DOI: 10.2147/NDT.S13830. 29. Zink M, Henn AF, Thome J. Combination of amisulpride and olanzapine in treatment resistant schizophrenia psychoses. European Psychiatry. 2004; 19:56-58. DOI: 10.1016/j.eurpsy.2003.09.002. 30. Sagud, M., Vuksan-Ćusa, B., Zivković, M., Vlatković, S., Kramarić, M., Bradaš, Z., & Mihaljević-Peleš, A. (2013). Antipsychotics: to combine or not to combine?. Psychiatria Danubina. 2013 Sep;25(3), 306–310. PMID: 24048402. 31. Leucht S., Crippa A., Siafis S., Patel MX., Orsini N., Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia . American Journal of Psychiatry. 2020 Apr 1; 177 (4): 342-353. DOI: 10.1176/appi.ajp.2019.19010034. 32. Roh D, Chang JG, Kim CH, Cho HS, An SK, Jung YC. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Australian & New Zealand Journal of Psychiatry. 2014 Jan;48(1):52-60. DOI: https://doi.org/10.1177/0004867413488221 33. Murck, H., Laughren, T., Lamers, F., Picard, R., Walther, S., Goff, D., & Sainati, S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innovations in clinical neuroscience. 2015 Mar-Apr; 12(3-4), 26S–40S. PMID: 25977838. 34. Martinuzzi, E., Barbosa, S., Daoudlarian, D., Bel Haj Ali, W., Gilet, C., Fillatre, L., Khalfallah, O., Troudet, R., Jamain, S., Fond, G., Sommer, I., Leucht, S., Dazzan, P., McGuire, P., Arango, C., Diaz-Caneja, C. M., Fleischhacker, W., Rujescu, D., Glenthøj, B., Winter, I., … OPTiMiSE Study Group (2019). Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational psychiatry, 9(1), 20. https://doi.org/10.1038/s41398-018-0366-5. 35. Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic combinations for schizophrenia. The Cochrane database of systematic reviews, 6(6), CD009005. https://doi.org/10.1002/14651858.CD009005.pub2. 36. Guinart, D., & Correll, C. U. (2020). Antipsychotic polypharmacy in schizophrenia: why not?. The Journal of clinical psychiatry. 2020 Apr 28;81(3): 19ac13118. 37. Gardner, K. N., & Bostwick, J. R. (2012). Antipsychotic treatment response in schizophrenia. American journal of health-system pharmacy: AJHP : official journal of the American Society of Health-System Pharmacists, 69(21), 1872–1879. DOI: https://doi.org/10.2146/ajhp110559. 38. Targum, S. D., Pestreich, L., Reksoprodjo, P., Pereira, H., Guindon, C., & Hochfeld, M. (2012). A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. Human psychopharmacology, 27(5), 455–463. https://doi.org/10.1002/hup.2247. 39. Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O., ... & Scatton, B. J. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 1997 Jan;, 280(1), 83-97. PMID: 8996185. 40. NICE. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years. Technology appraisal guidance [TA213]. Published date: 26 January 2011. https://www.nice.org.uk/guidance/TA213. 41. Hsu, CW., Lee, SY. & Wang, LJ. Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan. Eur Child Adolesc Psychiatry 28, 759–767 (2019). https://doi.org/10.1007/s00787-018-1242-9. 42. Rademaker M. (2001). Do women have more adverse drug reactions?. American journal of clinical dermatology, 2(6), 349–351. https://doi.org/10.2165/00128071-200102060-00001. 43. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45(5):243-253. https:// doi.org/10.1159/000022097. 44. Huhn, M., Nikolakopoulou A., D., Schneider-Thoma J., Krause M., Samara M. [et al.] (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 394(10202), 939-951. DOI: https://doi.org/10.1016/S0140-6736(19)31135-3